Abstract 4018
Background
A better understanding of real-world treatment (tx) patterns and associated clinical outcomes in the rapidly changing landscape of NSCLC is critical for informing clinical decision-making and maximising pt benefits. The SCAN-LEAF project aims to describe epidemiology, clinical care and outcomes of NSCLC pts in Scandinavia. Here, we report tx patterns and outcomes in pts with incident stage IIIB-IV NSCLC in 2 university hospitals in Sweden.
Methods
This retrospective cohort study includes all adult pts diagnosed with stage IIIB-IV NSCLC from 2012–2015, and followed in Uppsala and Stockholm University hospitals (follow-up until end of 2016). Electronic medical records were extracted and linked with national registries. Lines of therapy (LoTs) were defined using an algorithm based on systemic anticancer therapy (SACT). Descriptive results are shown by histology. Ongoing analyses will assess LoTs by mutation status, time to next LoT and overall survival using the Kaplan–Meier method.
Results
1625 pts diagnosed at stage IIIB-IV were identified (58.5% of all incident NSCLC). Mean age was 69.1 yrs (13.6% ≥80 yrs) and 49.5% were male. Histology distribution was: 70.9% non-squamous cell carcinoma (NSQ), 17.7% squamous-cell carcinoma (SQ), 10.3% not otherwise specified (NOS) and 3.4% other NSCLC. Of 831 EGFR-tested pts (51.1%), 21.2% had mutant EGFR; of 612 ALK-tested pts (37.7%), 10.0% had ALK translocations; of 33 PD-L1-tested pts (2.0%), 45.5% had PD-L1 expression ≥1%. Overall, 888 pts (54.7%) received a 1st LoT, of whom, 276 received a 2nd LoT (31.1%). SACT regimens are shown in the table.Table: 1484P
| SACT regimens in stage IIIB-IV NSCLC (used in ≥ 5 patients) | All NSCLC | NSQ | SQ | NOS |
|---|---|---|---|---|
| 1st line of therapy, % | (N = 888) | (N = 638) | (N = 119) | (N = 99) |
| Platinum-based chemotherapy | 80.3 | 77.4 | 88.2 | 87.9 |
| Non-platinum single agent | 5.2 | 4.4 | 6.7 | 6.1 |
| Tyrosine kinase inhibitor (mainly erlotinib) | 14.4 | 18.0 | 5.0 | 6.1 |
| 2nd line of therapy, % | (N = 276) | (N = 201) | (N = 40) | (N = 24) |
| Platinum-based chemotherapy | 23.6 | 19.9 | 30.0 | 25.0 |
| Non-platinum single agent | 56.5 | 55.7 | 62.5 | 66.7 |
| > Docetaxel | 39.5 | 37.3 | 47.5 | 54.2 |
| > Pemetrexed | 8.7 | 10.9 | 2.5 | 4.2 |
| > Vinorelbine | 8.0 | 7.5 | 12.5 | 8.3 |
| Tyrosine kinase inhibitor | 19.6 | 24.4 | 5.0 | 8.3 |
| > Erlotinib | 8.4 | 10.0 | 5.0 | 0.0 |
| > Crizotinib | 6.9 | 9.5 | 0.0 | 0.0 |
| > Afatinib | 2.9 | 3.5 | 0.0 | 4.2 |
Conclusions
During the 2012-2016 period (mainly prior to immunotherapy reimbursement), approximately half of incident stage IIIB-IV pts received a 1st LoT and only one-third of those received a 2nd LoT, mostly with non-platinum chemotherapy or tyrosine kinase inhibitors. Almost half of stage IIIB-IV NSCLC pts remained untreated after diagnosis (no SACT regimen).
Clinical trial identification
Legal entity responsible for the study
Bristol-Myers Squibb.
Funding
Bristol-Myers Squibb.
Editorial Acknowledgement
Disclosure
S. Ekman: Grants: Bristol-Myers Squibb, during the conduct of the study. P. Horvat, D. Layton, J. Kim, M. Rosenlund: Employee: IQVIA. A. Juarez-Garcia: Employee: Bristol-Myers Squibb. H.C. Jacobs: Personal fees: Bristol-Myers Squibb, during the conduct of the study. L. Lacoin: Consultant epidemiologist contracted: Bristol-Myers Squibb for the SCAN-LEAF project. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract